Lipocine vs Xenon Pharmaceuticals
LPCN and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and XENE compare
Xenon Pharmaceuticals is the larger company, worth 278 times as much as Lipocine ($3.9B against $14.1M).
Lipocine grew revenue faster over the last twelve months (−13.4% versus −100% for Xenon Pharmaceuticals).
Lipocine scores higher on the StockData Score (11 against 7 for Xenon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $14.1M | $3.9B |
| Share price | $1.71 | $40.48 |
| Change, 1 year | −41.4% | 2.0% |
| Change, 5 years | −91.4% | 39.6% |
| Beta (5Y) | 0.66 | 0.62 |
| Employees | 14 | 370 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× | – |
| P/B | 0.7× (better) | 3.4× |
| FCF yield | – | −9.1% |
| Fair value | $3.29 | – |
| Margin of safety | 48.0% | – |
| Growth | ||
| Revenue growth (TTM) | −13.4% (better) | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Operating margin | −269% | – |
| Net margin | −249% | – |
| Return on equity | −52.9% | −50.3% (better) |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.36 | 21.19 (better) |
| Altman Z-score | −9.08 | 41.77 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −114% | – |
| Shareholder yield | −114% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 104% |
| Held by insiders | 8.4% | 0.17% |
| Insider net buying, 12 months | $517K (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.3% | 7.6% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.